HeyJaredPharmaTimes
PharmaTimes is a specialist trade news outlet focused on the pharmaceutical and life sciences sector, with an emphasis on drug development, commercial strategy, and industry policy.
- Indexed articles, last 90 days
- 54
- Latest publication
- Sep 30, 2026
- Audience
- Top 5M sites
- Earliest in this view
- Jul 6, 2026
Latest articles
A new hope - PharmaTimes (opens the original)
Read excerpt
While advances in treatment mean that more than 80% of children diagnosed with cancer now survive for five years or more, cancer remains the leading cause of death in children under 14 in England and Wales. To mark Childhood Cancer Awareness Month, Health and Care Research Wales has brought together some of Wales’s leading voices in paediatric oncology research to discuss why access to research opportunities is vital for children and young people with cancer, and how close collaboration between
Here to maternity - PharmaTimes (opens the original)
Read excerpt
Maternity care is one of the most fundamental components of any healthcare system. It shapes not only the health of mothers and babies, but the long-term well-being of families and communities. Yet maternity services in the UK remain under intense scrutiny.Recent investigations have highlighted unacceptable failures in care and persistent inequalities. Too many opportunities to prevent harm have been missed. While most women receive excellent care from dedicated NHS professionals, too many famil
Investor horizons ahead of CPHI 2026 - PharmaTimes (opens the original)
Read excerpt
The core merits of outsourcing drug research, development, manufacturing and packaging have been long established over 20 years of PE investment – access to specialist technology and expertise, cost advantages and accelerated speed to market. It is a testament to investor success that over 100 exhibitors at CPHI 2026 have some form of PE ownership across the entire value chain of outsourced pharma services, from excipients and APIs to FDFs and packaging (Figure 1). Nevertheless, navigating today
Lexeo expands Friedreich ataxia pipeline with Mantle deal (opens the original)
Read excerpt
Acquisition adds new frataxin‑targeted modalities
AC immune reports week-100 progress in VacSyn trial (opens the original)
Read excerpt
Phase 2 data show strong safety and immunogenicity
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 5M sites
Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.